SEC Form 4 · accession 0001178913-26-003952
Entera Bio Ltd. · ENTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Hillel Galitzer
Officer — Chief Operating Officer
Period of report
Aug 7, 2026
Accepted (ET)
Aug 7, 2026 · 4:19 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001638097
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.37 | Aug 7, 2026 | A | 200,000 | A | — | May 7, 2036 | Ordinary Shares, par value NIS 0.0000769 per share | 200,000 | 200,000 | D |
Explanation of responses
- F1Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).